Turn precision medicine into action

When you’re driven to improve cancer patients’ lives, turn to a leader in oncology clinical trial development.

Through CerbACT, our immuno-oncology Center of Excellence, we empower precision medicine research by applying deep and wide biomarker expertise, translational research, and clinical development strategy.

From our purpose-built lab facility in Taiwan, CerbACT Asia supports I/O drug developers globally with cutting edge technology in FCM, histopathology, immunohistochemistry, and NGS sequencing, to turn precision medicine into action.

Flow Cytometry

Expert development and validation of custom flow cytometry assay panels for your clinical trials

Histopathology and immunohistochemistry (IHC)

Exploratory and in vitro diagnostic testing, histopathology, and advanced IHC analysis

Genomics Testing

NGS testing for patient diagnostics

CerbACT is a joint venture between Cerba Research and ACT Genomics, developed to meet the needs of IO drug developers. A synergistic combination of expertise and capabilities to solve precision medicine challenges by advancing your research with a new platform combining deep scientific expertise and technical capabilities:

Cerba_IO CoE_Webchart_8-24-21_VF

For biotech, pharmaceutical, government, and non-government organizations, CerbACT turns precision medicine innovation into action.

Explore the CerbACT Asia Laboratory

Watch the below video for a glimpse at our facility in Taipei, and a short overview of the instruments and technology present to support you in your Immuno-oncology research.